Valneva's Pivotal Year: Clinical Data to Define Trajectory

Valneva's 2026 hinges on Phase 3 data for its Lyme vaccine VLA15 and Shigella candidate. Solid 2025 revenue sets stage for these pivotal clinical catalysts.

Investor attention is fixed on Valneva as it approaches two critical clinical milestones in 2026. While the company will release its full-year 2025 financial results on March 18, the market is looking further ahead. The primary catalyst is the anticipated release of final Phase 3 data for its Lyme disease vaccine candidate, VLA15, expected in the first half of 2026. This outcome is poised to impact the firm's valuation more significantly than any near-term earnings report.

A Stable Core Business Amid a Transitional Period

Preliminary figures for 2025 depict an organization on solid operational footing. Total revenues climbed to €174.7 million, with the core business of proprietary travel vaccines growing by an adjusted nine percent. However, management has provided a more cautious outlook for 2026, projecting revenues to fall between €155 million and €170 million. This forecast is attributed to the conclusion of third-party commercial agreements, which the company's own product sales cannot yet fully offset.

Valneva's liquidity position stood at €109.7 million at the end of 2025, a decrease from €168.3 million the prior year. Despite this reduction, a successful debt refinancing operation has secured necessary operational flexibility for the coming period.

The Lyme Disease Vaccine Candidate Nears Its Moment

The central focus for shareholders remains VLA15, a Lyme disease vaccine developed in collaboration with Pfizer. The pivotal Phase 3 trial, named VALOR, enrolled 9,437 participants aged five and older. The vaccine candidate employs a unique mechanism, targeting the outer surface protein A (OspA) of Borrelia burgdorferi. It is designed to block the bacteria before transmission from ticks to humans occurs, covering the six most prevalent serotypes in North America and Europe.

Pfizer intends to publish the final study data in the first six months of 2026. A positive readout would trigger regulatory submissions before the end of that same year. VLA15 currently holds the distinction of being the only advanced Lyme disease vaccine candidate in global clinical development.

In a clear sign of the upcoming catalyst's importance, CEO Thomas Lingelbach and CFO Peter Buhler are engaged in a series of investor meetings. Following appearances at the Jefferies Biotech Summit in Miami and the TD Cowen Health Care Conference in Boston, their schedule includes an event hosted by Van Lanschot Kempen in Amsterdam.

A Year Defined by Dual Clinical Catalysts

Beyond the Lyme disease program, Valneva anticipates another major data release in the latter half of 2026. Results are expected for its Shigella vaccine candidate, which the company notes is the world's most advanced candidate for this indication. Consequently, two potential pipeline inflection points are scheduled within a twelve-month window.

Market expectations are already shifting, reflected in the equity's performance. Valneva shares have gained approximately 29% since the start of the year, trading at €4.95. This price sits notably above its 200-day moving average of €3.86. The upcoming annual results on March 18 will provide the next formal update, but the definitive directional shift for the stock will likely arrive with Pfizer's Phase 3 data shortly thereafter.